Obama's Health Care Struggle -- Waterloo or Water Down?
by Bill Moyers & Michael Winship
July 25, 2009
The Republicans have more than health care reform in their bombsights -- they want a loss for Obama so crushing it will bring the administration to its knees and restore GOP control of Congress after next year's elections. In the words of Republican Senator Jim DeMint, "If we're able to stop Obama on this, it will be his Waterloo. It will break him."
President Obama rejected the Republicans' Waterloo metaphor and mounted a massive media counteroffensive of his own. But the President has already run into booby traps of his own making and minefields laid by members of his own party, exacerbated when the Congressional Budget Office reported that reform plans, instead of controlling costs, would send the national debt further into the stratosphere.
Meanwhile, supporters who want to scrap the present system for fundamental change are staring glumly though the fog of war at a battlefield in total disarray. They fear that in the White House's desire to get a bill -- any bill -- passed by Congress, it will have been so compromised, so bent to favor the big interests, that it will be less Waterloo than water down, a steady diluting of the change they had hoped for and that America needs.
The big drug companies are already so pleased with what they've been promised that they've brought back Harry and Louise -- the make-believe couple who starred in TV ads that helped torpedo the Clinton health care plan -- but this time they're in favor of reform.
.... as Alicia Mundy and Laura Meckler recently wrote in The Wall Street Journal, that "the pharmaceuticals industry, which President Barack Obama promised to 'take on' during his campaign, is winning most of what it wants in the health-care overhaul."
Their story describes "a string of victories" plucked from the Senate Finance Committee by drug company lobbyists, including no cost-cutting steps, no cheaper drugs to be allowed across the border from Canada, and no direct Federal government negotiations with the pharmaceutical companies to lower Medicare drug prices.
And that's not all. The Senate Health Committee is giving the biotech industry monopoly protection against competition from generic drugs for 12 years after they go on the market.
Please read the complete article at:
http://www.commondreams.org/view/2009/07/25